At a dose of 1.2 pmol kg− 1 min− 1 infused over 270 to 330 min, GLP-1 reduced the glycaemic response to small intestinal nutrient delivery in patients with T2DM [23] and to intra-gastric and small intestinal nutrient delivery in patients not known to have T2DM [21, 22, 30]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.